IGF-1/PI3K/AKT/FOXO signaling pathway as a possible pharmacological target in testosterone-induced benign prostatic hyperplasia in rats (PO.3.4.2) / (Record no. 169535)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 06251namaa22004331i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - أخر تعامل مع التسجيلة | |
| control field | 20250223033348.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 241217s2023 |||a|||f m||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloguing agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| -- | ara |
| 049 ## - Acquisition Source | |
| Acquisition Source | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.1 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 615.1 |
| Edition number | 21 |
| 097 ## - Degree | |
| Degree | M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Local Call Number | Cai01.08.09.M.Sc.2023.Ny.I |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Authority record control number or standard number | Nyera Hamdy Ibrahim, |
| Preparation | preparation. |
| 245 10 - TITLE STATEMENT | |
| Title | IGF-1/PI3K/AKT/FOXO signaling pathway as a possible pharmacological target in testosterone-induced benign prostatic hyperplasia in rats (PO.3.4.2) / |
| Statement of responsibility, etc. | by Nyera Hamdy Ibrahim ; Supervision of Dr. Rabab Hamed Sayed, Dr. Esraa Abd El-Aziz Kandil, Dr. Mai Amin Kamel. |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | / كهدف دوائي محتمل في تضخم البروستاتا الحميد المحدث بهرمون التستوستيرون في الجرذان IGF-1 / PI3K / AKT / FOXOمسار إشارات |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2023. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 120 pages : |
| Other physical details | illustrations ; |
| Dimensions | 25 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rda content |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (M.Sc.)-Cairo University, 2023. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 106-120. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Benign prostatic hyperplasia (BPH) is a common disease in elder men that has a major impact on their quality of life, it is distinguished by non-malignant enlargement of prostate cells leading to various lower urinary tract symptoms. BPH pathogenesis includes oxidative stress, apoptosis, androgens receptors signaling pathways and alternations in insulin growth factor (IGF) pathway. Regulating IGF-1/PI3K/AKT/FOXO signaling in addition to modulating apoptosis as well as oxidative stress can possibly protect cells from the elevated proliferation. Along with statins and nonsteroidal anti-inflammatory drugs (NSAIDs) common uses, they also possess anti-oxidant, anti-inflammatory and anti-tumor effects. The current study aims to determine simvastatin as well as piroxicam therapeutic effect on testosterone-induced BPH. Rats were randomly divided into six groups with 9 rats each. The control group received olive oil subcutaneously and distilled water orally for 30 consecutive days. The second group which was BPH-induced group received (3 mg/kg) testosterone enanthate dissolved in olive oil subcutaneously. Third group received simvastatin (20 mg/kg, p.o.) dissolved in distilled water. Fourth group received piroxicam (4 mg/kg, p.o.) dissolved in distilled water. Fifth group which is BPH-induced treated group received both simvastatin and testosterone and sixth group received both piroxicam and testosterone. Testosterone markedly elevated severity of histopathological alterations in prostate tissues, prostate index and 5-alpa reductase (5AR) enzyme level whereas simvastatin as well as piroxicam treatment significantly decreased them. Similarly, testosterone up-regulated IGF-1/PI3K/AKT signaling pathway while down-regulated FOXO transcription factor. Furthermore it reduced apoptotic markers level in prostatic tissue while it increased anti-apoptotic marker level. Additionally, it attenuated reduced glutathione (GSH) levels and superoxide dismutase (SOD) activity. Simvastatin as well as piroxicam treatment significantly reversed testosterone's effect on prostatic tissues. In conclusion, this study indicates that simvastatin and piroxicam are potential treatments for BPH which may be allocated to their impact on IGF-1/PI3K/AKT/FOXO signaling pathway along with their anti-oxidant and apoptotic impact on prostatic tissues. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | تضخم البروستاتا الحميد هو مرض شائع لدى كبار السن وله تأثير كبير على نوعية حياتهم ، ويتميز بتضخم غير خبيث لخلايا البروستاتا مما يؤدي إلى أعراض مختلفة في المسالك البولية السفلية . هناك العديد من العوامل التي تسبب تضخم البروستاتا الحميد مثل الإجهاد التأكسدي ، وموت الخلايا المبرمج ، ومستقبلات الأندروجين والتغيرات في مسار عامل النمو المشابه للإنسولين IGF. تنظيم إشارات IGF-1 / PI3K / AKT / FOXO بالإضافة إلى تعديل موت الخلايا المبرمج وكذلك الإجهاد التأكسدي يمكن أن يحمي الخلايا من الانتشار.<br/>إلى جانب الاستخدامات الشائعة للستاتين كدواء مخفض للكوليسترول واستخدام أدوية مضادات الالتهاب غير الستيروئيدية لعلاج الالتهابات الشديدة و تسكين الألم ، فإن تلك الأدوية تمتلك أيضًا تأثيرات مضادة للأكسدة ومضادة للأورام , بالاضافة لذلك أنها يمكن أن يكون لهم تأثيرعلى مسار عامل النمو المشابه للإنسولين IGF.<br/>الهدف من البحث<br/>تهدف هذه الدراسة إلى التحقيق في الآثار العلاجية للـسيمفاستاتين و البيروكسيكام في نموذج تضخم البروستاتا الحميد االمحدث بهرمون التستوستيرون في الجرذان عن طريق دراسة تأثير تعديل مسار إشارات IGF-1 / PI3K / AKT / FOXO الذي يتم بواسطة هذا الدواء. |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Issues CD | Issues also as CD. |
| 546 ## - LANGUAGE NOTE | |
| Text Language | Text in English and abstract in Arabic & English. |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Durgs |
| Source of heading or term | qrmak |
| 653 #0 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Benign prostatic hyperplasia |
| -- | Simvastatin |
| -- | Piroxicam |
| -- | IGF-1 |
| -- | PI3K |
| -- | AKT |
| -- | FOXO |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Rabab Hamed Sayed |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Esraa Abd El-Aziz Kandil |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mai Amin Kamel |
| Relator term | thesis advisor. |
| 900 ## - Thesis Information | |
| Grant date | 01-01-2023 |
| Supervisory body | Rabab Hamed Sayed |
| -- | Esraa Abd El-Aziz Kandil |
| -- | Mai Amin Kamel |
| Universities | Cairo University |
| Faculties | Faculty of Pharmacy |
| Department | Department of Pharmacology and Toxicology |
| 905 ## - Cataloger and Reviser Names | |
| Cataloger Name | Shimaa |
| Reviser Names | Huda |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Home library | Current library | Date acquired | Inventory number | Full call number | Barcode | Date last seen | Effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 17.12.2024 | 89523 | Cai01.08.09.M.Sc.2023.Ny.I | 01010110089523000 | 17.12.2024 | 17.12.2024 | Thesis |